




RealRate

# PHARMACEUTICAL 2022

Virpax Pharmaceuticals Inc.  
Rank 177 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence • [www.realrate.ai](http://www.realrate.ai)

**RealRate**

# PHARMACEUTICAL 2022

Virpax Pharmaceuticals Inc.  
Rank 177 of 475



The relative strengths and weaknesses of Virpax Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Virpax Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 247% points. The greatest weakness of Virpax Pharmaceuticals Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 63% points.

The company's Economic Capital Ratio, given in the ranking table, is -37%, being 239% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	39,572
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,088
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	93
Other Liabilities	0
Other Net Income	0
Property and Equipment	0
Research and Development	4,839
Revenues	62
Selling, General and Administrative Expense	7,186

Output Variable	Value in 1000 USD
Assets	39,572
Liabilities	2,088
Expenses	12,118
Stockholders Equity	37,485
Net Income	-12,056
Comprehensive Net Income	-12,056
Economic Capital Ratio	-37%

**RealRate**

• Financial Strength Rankings using Artificial Intelligence • [www.realrate.ai](http://www.realrate.ai)